N-甲基-(3-甲基异噁唑-5-甲基)胺 | 401647-22-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基-(3-甲基异噁唑-5-甲基)胺
• 中文别名: N-甲基-1-(3-甲基异恶唑-5-基)甲胺
• 英文名称: N-methyl(3-methylisoxazol-5-yl)methanamine
• 英文别名: N-methyl-1-(3-methylisoxazol-5-yl)methanamine；N-methyl-1-(3-methyl-1,2-oxazol-5-yl)methanamine
• CAS: 401647-22-1
• 化学式: C₆H₁₀N₂O
• mdl: MFCD08060065
• 分子量: 126.158
• InChiKey: UQKWKRSUELRKSK-UHFFFAOYSA-N

物化性质

• 沸点：
  86-87 °C(Press: 3 Torr)
• 密度：
  0.9981 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  、 N-甲基-(3-甲基异噁唑-5-甲基)胺 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 (+/-)-1-[4-[(3-methyl-3-(5-methylisoxazolyl-3-methyl)amino)-propyl]-1-(2,5-difluorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-3-yl]ethanone
  参考文献：
  名称：

  Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP

  摘要：

  Inspired by previous efforts in the pyrazolobenzoxazine class of KSP inhibitors, the design and synthesis of 1,4-diaryl-4,5-dihydropyrazole inhibitors of KSP are described. Crystallographic evidence of binding mode and in vivo potency data is also highlighted. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.074
• 作为产物：
  描述：

  5-氯甲基-3-甲基异噁唑 、 甲胺 在 三乙胺 作用下， 以 水 、 苯 为溶剂， 反应 5.0h， 以80%的产率得到N-甲基-(3-甲基异噁唑-5-甲基)胺
  参考文献：
  名称：

  Reaction of 3-alkyl(aryl)-5-chloromethylisoxazoles with nucleophilic reagents

  摘要：

  Previously unknown 3-alkyl(aryl)isoxazoles containing various functional groups in the 5-position were synthesized by reactions of 3-alkyl(aryl)-5-chloromethylisoxazoles with nucleophiles (2-aminoethanol, methylamine, sodium acetate, and sodium methoxide).

  DOI：

  10.1134/s1070428011100149

文献信息

• DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS
  申请人：Badorc Alain

  公开号：US20120277205A1

  公开（公告）日：2012-11-01

  The present invention relates to compounds corresponding to formula (I): in which: A represents a divalent aromatic radical; X represents a —CH— group or a nitrogen atom; R 1 represents a (C 1 -C 4 )alkyl or a (C 1 -C 4 )alkoxy; R 2 represents a group Alk; R 3 represents a hydroxyl or a group —NR 7 R 8 ; R 4 represents a hydrogen atom, a halogen atom, a cyano, a phenyl, a group Alk, a group OAlk or a group —NR 9 R 10 ; R 5 represents a hydrogen atom, a halogen atom or a group Alk; R 6 represents a hydrogen atom, a halogen atom, a cyano, a group —COOAlk or a —CONH 2 group.

  该发明涉及与式(I)对应的化合物：其中：A代表二价芳香基团；X代表一个—CH—基团或一个氮原子；R1代表(C1-C4)烷基或(C1-C4)烷氧基；R2代表一个烷基基团；R3代表一个羟基或一个基团—NR7R8；R4代表氢原子、卤素原子、氰基、苯基、烷基基团、氧烷基团或基团—NR9R10；R5代表氢原子、卤素原子或一个烷基基团；R6代表氢原子、卤素原子、氰基、基团—COOAlk或基团—CONH2。
• NOVEL COMPOUNDS
  申请人：Buttar David

  公开号：US20080153812A1

  公开（公告）日：2008-06-26

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一个式(I)的化合物，或其药用可接受的盐。还提供了制备式1化合物的方法，以及将式1化合物用作药物和用于癌症治疗的用途。
• Pteridinone derivatives as modulators of chemokine receptor activity
  申请人：Bonnert Victor Roger

  公开号：US20050010047A1

  公开（公告）日：2005-01-13

  The invention provides certain pteridinone compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的某些蝶呤酮化合物，用于其制备的过程和中间体，含有它们的制药组合物以及它们在治疗中的应用。
• CHEMICAL COMPOUNDS
  申请人：Jones Lyn Howard

  公开号：US20090264425A1

  公开（公告）日：2009-10-22

  This invention relates to biaryl ether derivatives of formula (I) wherein R 1 , R 3 , R 4 , X, W, Y and m are defined in the description, and to compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof.

  本发明涉及公式（I）的二芳基醚衍生物，其中R1、R3、R4、X、W、Y和m在说明中定义，并涉及含有它们的组合物以及这些衍生物的用途。本发明的化合物与酶逆转录酶结合，并且是其调节剂，特别是抑制剂。
• Pteridinone Derivatives as Modulators of Chemokine Receptor Activity
  申请人：Bonnert Victor Roger

  公开号：US20070142352A1

  公开（公告）日：2007-06-21

  The invention provides certain pteridinone compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了某些式（I）的蕨酮类化合物，用于它们的制备的过程和中间体，包含它们的制药组合物以及它们在治疗中的应用。